Company Overview of Lifecore Biomedical, LLC
Lifecore Biomedical, LLC develops, manufactures, and markets hyaluronan-based materials and medical products for ophthalmic, orthopedic, and veterinary markets worldwide. It offers pharmaceutical grade sodium hyaluronate for use in various medical applications; sterile pharmaceutical grade sodium hyaluronate in various molecular weights; and sodium hyaluronate for research use. The company also provides biohydrogel, a hyaluronan hydrogel based on di-hydroxyphenyl linkages of tyramine substituted sodium hyaluronate; and hyaluronan based biomaterials for the academic and corporate research communities. In addition, it offers design and development, contract fermentation and purification, and a...
3515 Lyman Boulevard
Chaska, MN 55318
Founded in 1965
Key Executives for Lifecore Biomedical, LLC
Senior Director of Finance
Chairman of Landec Corp and Chief Executive Officer of Landec Corp
Chief Scientific Officer and Vice President
Vice President and General Manager
Compensation as of Fiscal Year 2016.
Lifecore Biomedical, LLC Key Developments
Lifecore Biomedical Invests Expanding in Chaska
Aug 26 15
Lifecore Biomedical will invest $18 million and create 68 jobs in an expansion of its facilities in Chaska. The company said it plans to expand an existing facility at 3515 Lyman Blvd. by 25,000 square feet to create room for a medical manufacturing clean room and quality control laboratory. The new jobs, which will be created within three years.
Heron Therapeutics, Inc. Enters into Commercial Manufacturing Services Agreement with Lifecore Biomedical, LLC
May 29 15
Effective May 27, 2015, Heron Therapeutics Inc. entered into a commercial manufacturing services agreement, with Lifecore Biomedical, LLC. Pursuant to the agreement, Lifecore will manufacture the Company's lead product candidate, SUSTOL (granisetron injection, extended release), for commercial use, subject to FDA approval. The Company will provide Lifecore with certain raw materials, equipment and proprietary information necessary in connection with the manufacturing services, as well as binding and non-binding forecasts for the purchase of SUSTOL, which Lifecore is required to manufacture, subject to certain terms and conditions. The initial term of the Agreement is seven years from the effective date, subject to early termination under certain circumstances, and renewal options.
Lifecore Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 1, 2015
Mar 31 15
Lifecore announced unaudited earnings results for the third quarter and nine months ended March 1, 2015. For the quarter, the company reported revenue of $14,799,000 against $20,176,000 a year ago, due to expected lower shipments from a one-time inventory adjustment by a key Lifecore customer. Net income was $4,099,000 against $9,691,000 a year ago.
For the nine months, the company reported revenue of $29,928,000 against $37,539,000 a year ago. Net income was $3,406,000 against $10,936,000 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|